The lack of relevant in vitro neural models is an important obstacle on medical progress for neuropathologies. Establishment of relevant cellular models is crucial both to better understand the pathological mechanisms of these diseases and identify new therapeutic targets and strategies. To be pertinent, an in vitro model must reproduce the pathological features of a human disease. However, in the context of neurodegenerative disease, a relevant in vitro model should provide neural cell replacement as a valuable therapeutic opportunity.
Introduction
The World Health Organization (WHO) classifies astrocytomas as low grade (grade I to II) or high grade (grade III and IV). Glioblastoma multiforme (GBM) is an astrocytoma grade IV, the most lethal of primary brain tumors, that is resistant to all current forms of treatments 1 . Despite standard-of-care therapy including neurosurgery, chemotherapy, and radiotherapy, GBM remains fatal and the 15-month overall survival rate has not dramatically changed over the past 15 years 2 . To make significant progress in understanding GBM pathogenesis, the use of relevant models is key. So far, the study of GBM has relied on cell lines, rodent organotypic slices, and xenotransplantation of patient-derived cells into mice or transgenic mice developing spontaneous tumors 3, 4 . Although these models have been useful to study brain metastasis and tumor aggressiveness, they are restricted by differences among species, and resulting conclusions may be incorrectly translated to human tissues. Moreover, existing models with human cells are also limited by the absence of host tissue/tumor interactions 3, 4 . Experimental models are critical for the translation from basic science to therapeutic targets. Therefore, describing a protocol to produce in vitro human neural organoids cocultured with GBM-initiating cells (GICs) can provide a relevant system that mimics morphological and functional features of GBM development. This system reproduces some in vivo features of GBM developmentsuch as diffuse migration of invading cells and necrosis areas, and it highlights gene expression relevant to tumor biology. As previously revealed, some critical microRNAs are induced during GIC development within 3D nervous tissue 5, 6 . PD is a major neurodegenerative disorder and associated with the degeneration of multiple neuronal subtypes 7 . Even if a progressive onset of symptoms (e.g., bradykinesia, asymmetric rest tremor, rigidity and posture instability) characterizes the disease, its exact etiology is not clearly established. Indeed, many studies have highlighted evidence that major risk factors can result from a combination of genetic and environmental factors. Parkinsonian symptoms are associated with the bilateral degeneration of dopaminergic neurons in the substancia nigra (SN), leading to the disappearance of dopaminergic (DA) axons projecting to the striatum 8, 9 . Therefore, the reduction of striatal dopamine levels is correlated with progression of motor dysfunction in PD patients. Dopaminergic neurons contain tyrosine hydroxylase (TH), a key enzyme in the synthesis of catecholaminergic neurotransmitters that converts the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA, a dopamine precursor) to dopamine 10 . Early loss of TH activity followed by a decline in TH protein expression is a hallmark of PD.
This study describes two protocols using human neural organoids, with one specifically oriented towards a midbrain-like phenotype enriched with TH-positive cells.
Protocol
This protocol follows the guidelines of University of Geneva's human research ethics committee.
1. Maintenance and culture of undifferentiated human embryonic stem cells (hESCs) 1 . Perform maintenance and expansion of hSECs on feeder-free conditions by pre-coating dishes with a specific extracellular matrix.
1. Thaw 300 µL of extracellular matrix at 4 °C (typical range concentration 18-22 mg/mL, keep on ice) and gently mix with 15 mL of cold DMEM medium to avoid a premature gelation of the extracellular matrix. Add 7.5 mL of the extracellular matric to both T150 flasks. 2. Incubate the dishes coated with extracellular matrix at 37 °C for at least 1 h (maximum overnight). 3. Remove the medium and seed hESCs to a density of 6.5 x 10 4 cell/cm 2 .
2. Maintain H1 (hESC cell line) in hESC medium and 1% penicillin/streptomycin. 3. Pass the cells with enzymatic procedure: add 7.5 mL of enzymatic solution to a T75 cm 2 flask over a period of 1-2 min at 37 °C. Once cells are completely detached, add 7.5 mL of DMEM-F12 then centrifuge for 5 min at 300 x g. To allow for better survival, re-plate cells at the desired density onto extracellular matrix-coated dishes, in the same medium containing Rho-associated protein kinase (ROCK) inhibitor (10 µM) for 24 h.
hESC-derived neural organoids for GBM studies
1. 24 h before starting the 3D culture, replace the hESC medium with a serum-free medium supplemented with 10 µM ROCK inhibitor (both components are necessary to support cell survival and spontaneous neurosphere formation during the aggregation phase in a microwell plate). The cells should be at 60% confluency. The next day (day 0), detach hESC colonies as single cells: remove the medium, then rinse with PBS without Ca
, add 5 mL of enzymatic dissolution solution, and incubate at 37 °C for 1-2 min. 2. Collect the cells in serum-free medium with 10 µM of ROCK inhibitor and centrifuge the cells at 300 x g for 5 min. Remove the supernatant and count the cells in 10 mL of serum-free medium supplemented with 10 µM of ROCK inhibitor. 3. In parallel, rinse the microwell plate with 2 mL of serum-free medium per well and centrifuge the plate at 1200 x g for 5 min to remove all bubbles, which can prevent neurosphere formation. 4. Prepare 28.2 x 10 6 of cells in 12.5 mL of serum-free medium supplemented with 10 µM ROCK inhibitor. Dispense 1000 cells/microwell.
Centrifuge the cells at 300 x g for 5 min and place the plate in the incubator at 37 °C overnight (maximum 36 h). For example: to obtain 30 human neural organoids, use one T150 flask at 70%-80% of confluence (about 30 million cells). 5. The next day (day 1), collect the spheres (with a P1000) and place them in a 6 well plate. In each well, add 2 mL of B27 medium and DMEM-F12 GlutaMAX and Neurobasal medium (mix at 1:1), supplemented with 1% B27 supplements and 1% non-essential amino acids (NEAA). To promote fast neural induction, supplement the medium with dual-SMAD inhibition cocktail, composed of 10 µM TGFβ/Activin/Nodal inhibitor and 0.5 µM bone morphogenic protein (BMP) inhibitor. From this step forward, the spheres are cultured in rotation (60 rpm, orbital shaker). The rotation is critical to prevent the spheres from sticking together or to the plate. 6. Change the medium every 2-3 days: bend the plate and let the spheres fall down for 5 min, remove half of the medium (2 mL), and add 2 mL of fresh B27 medium supplemented with growth factors and inhibitors. Do not centrifuge the spheres. 7. Perform neural induction according to the following time course:
1. From days 1-4, culture the spheres in B27 medium supplemented with dual-SMAD. The dual-SMAD inhibition cocktail (10 µM TGFβ/ Activin/Nodal inhibitor and 0.5 µM BMP inhibitor) promote the neural induction. 2. From days 4-11, promote proliferation of hESC-derived neural rosettes (into the spheres), by adding 10 ng/mL epidermal growth factor (EGF) and 10 ng/mL basic fibroblast factor (bFGF) to the B27 medium supplemented with dual-SMAD cocktail. NOTE: On day 11, most of the cells should be positive for Nestin. 3. From days 11-13, culture the spheres in B27 medium supplemented with 0.5 µM BMP inhibitor. 4. From days 13-21, culture the spheres in B27 medium supplemented with 10 ng/mL glial derived neurotrophic factor (GDNF), 10 ng/mL brain derived neurotrophic factor (BDNF) and 1 µM of γ-secretase inhibitor. GDNF and BDNF promote neuronal and glial differentiation. The γ-secretase inhibitor allows for greater neural maturation. 5. On day 21, plate the spheres (about 1,000 spheres) on a hydrophilic polytetrafluoroethylene (PTFE) membrane (6 mm diameter, 0.4 µm) deposited on a culture plate insert designed for 6 well plate. Stop any rotation from this step. The presence of rosettes, observed with a bright-field microscope, indicate the initiation of neural differentiation. The neural rosettes can be observed 2-3 days after plating spheres on the PTFE membrane. 6. Add 1 mL of B27 medium supplemented with growth factors and inhibitors (as followed) to each well underneath the membrane insert, every 2-3 days (usually on Monday, Wednesday and Friday), for a following 3 weeks of differentiation. 7. From days 21-25, cultivate human neural organoids in the same neural maturation medium (Cf. step 2.7.4). 8. From days 25-28, only complement B27 medium with 1 µM γ-secretase inhibitor. 9. From days 28-39, stop adding the γ-secretase inhibitor and continue human neural organoid culture in B27 medium only.
hESC-derived dopaminergic organoids for PD studies
1. Day 0: Amplify hESCs in 2D culture up to 60% confluency (day 0), then replace stem cell media used to maintain pluripotency features of hESCs with a serum-free medium. Start neural induction by supplementing culture medium with 0.5 µM BMP inhibitor and 10 µM TGFβ/ Activin/Nodal inhibitor (dual-SMAD inhibition cocktail), then add 10 µM ROCK inhibitor for 24 h to increase the survival rate of cells during passage. 2. Day 1: Prepare the microwell plate with 2.5 mL per well of serum-free medium supplemented with 0.5 µM BMP inhibitor, 10 µM TGFβ/Activin/ Nodal inhibitor, and 10 µM ROCK inhibitor. To specify cells towards the ventral pattern of the neural tube, add 100 ng/mL Sonic Hedgehog (SHH), 100 ng/mL fibroblast growth factor 8 (FGF8), and 2 µM smoothened agonist. Centrifuge the plate (only with medium and without cells) at 1200 x g for 5 min to remove air bubbles from the microwells. to prepare the microwell plate. 3. Adjust the medium volume to obtain a cell suspension allowing to form neurospheres containing 1000 cells per microwell (for example, the microwell plate used here contains 4,700 microwells per well). So, prepare 4.7 million cells in 2.5 mL of medium and add it to the previous 2.5 mL of medium already placed in the plate. 4. In order to correctly distribute the cells in each microwell, gently shake the plate, and centrifuge the microwell plate 300 x g for 5 min.
Incubate the plate at 37 °C for 24 h to generate spheres.
Day 2:
Gently flush the microwells with the medium and collect then transfer the spheres in tissue-treated six-well plate. Replace medium with Neurobasal medium supplemented with 1% B27, 1x NEAA, 2 mM L-glutamine, and 1% of penicillin/ streptomycin. Additionally, add regionalization factors SHH, FGF8, smoothened agonist, and dual-SMAD inhibition small molecules. 1. Place spheres in rotation at 37 °C (60 rpm, orbital shaker) and change half-medium freshly supplemented every 2-3 days.
Day 3:
To enhance neural induction and convert to neural progenitors with a midbrain identity, supplement the medium with 3 µM GSK-3β inhibitor, which activates the Wnt/β-catenin pathway. Maintain GSK-3β inhibitor in the medium up to day 13. Split into two new tissue-treated 6 well plates to reduce both sphere density per well and avoid sphere aggregation. NOTE: At Day 8, most of the cells should be positive for Nestin. 5. Day 8: Start the neural maturation: replace regionalization factors SHH, FGF8, smoothened agonist, and dual-SMAD inhibition cocktail with 0.5 mM dibutyryl cAMP (to favor maturation), 20 nM inhibitor of histone deacetylase (for cell cycle exit), 1 µM γ-secretase inhibitor and growth factors, 10 ng/mL GDNF, 10 ng/mL BDNF, 1 ng/mL transforming growth factor β3 (TGFβ3), and 5 ng/mL FGF20 (both favor DA progenitor survival). Change the medium every 2-3 days. 6. Day 21: Generate the neural organoid: seed around 100 neurospheres under air-liquid interface conditions on PTFE membrane (6 mm diameter). Transfer the membrane to a culture plate insert (0.4 mm) and add 1.2 mL of neural maturation medium used for neurosphere differentiation as previously described. 1. Stop any rotation from this step. Change the medium every 2-3 days until the required differentiation time point is achieved. NOTE: Regarding neural maturation, a decrease of the neural immature marker Nestin and increase of mature neural markers β3-tubulin and GFAP were observed. High TH and NURR1 expressions were observed ( Figure 3C ) and confirm neural organoid maturity 11 . 
Quantification of TH and Nurr1 gene expression for validation of dopaminergic differentiation

Discussion
One of the most critical aspects of this protocol includes the maintenance of hESC pluripotency during cell culturing and close monitoring of the spheres and neural organoid morphology. hESCs are very sensitive, and every manipulation can lead to early uncontrolled differentiation as well as cell death. In order to increase experimental reproducibility and avoid the occurrence of abnormal karyotype events, it is advised to cryopreserve several batches of hESCs at the lowest passage after validation of their chromosome stability. Moreover, it is recommended to thaw a new vial for each experiment and check the behavior of the cells every day. If the spheres are less refractive with abnormal higher size, they will likely start to aggregate and die.
One improvement upon this system is either perfusion or implementing a vascularized system (by adding endothelial cells or within a 3D fluidic microchip) 12, 13 . However, controlling the thickness of the neural organoid (≤300 µm) allows efficient passive perfusion of oxygen and nutriments and prevents necrosis. Another improvement is the introduction of immune cells (microglia). With these limitations in mind, neural organoids plus a GIC system may be a relevant tool for several reasons. First, this system allows drug screening to monitor how a therapeutic compound may affect an organoid or tumor cell. Second, cell-to-cell interactions can be studied, and micro-environmental determinants underlying individual and collective invasions can be visualized and explored 5, 6, 13 .
In the context of Parkinson's disease, a neural organoid enriched in DA neurons can represent a relevant and accurate 3D model to study disease development. In previous studies, Parkinson's patient-derived induced pluripotent stem cells differentiated towards DA neurons have been used to study the affected neuronal subtypes. Of note, some disease-related phenotypes such as the accumulation of α-synuclein and sensitivity to oxidative stress have been observed 14, 15 . Moreover, the neural organoid may be used as a tool to screen therapeutic molecules. However, specific and relevant readouts should be set up to evaluate DA neuron survival and functionality, such as dopamine production and electrophysiological activity. Altogether, this protocol provides two standardized and accurate stem cell-based approaches to generate neural organoids.
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